A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults

Respiratory Medicine

Volumn 94, Issue 4, 2000, Pages 337-344

  Siegert, R ^a   Gehanno, P ^b   Nikolaidis, P ^c   Bagger Sjoback D ^d   Ibanez, J M ^e   Hampel, B ^f   Sommerauer, B ^g  

^a PROSPER HOSPITAL   (Germany)

^b BICHAT HOSPITAL   (France)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e Manresa General Hospital   (Spain)

^f BAYER AG   (Germany)

^g Bayer France   (France)

Author keywords

Antibiotic; Bacterial sinusitis; Clinical trial; Moxifloxacin

Indexed keywords

CEFUROXIME AXETIL; MOXIFLOXACIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RADIOLOGY; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYMPTOM; VERTIGO; VOMITING;

EID: 0034077723     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.1999.0769     Document Type: Article

References (27)

1. Brook I. Microbiology and management of sinusitis. J Otolaryngol. 25:1996;249-256.
2. Gwaltney J M, Sydnor A, Sande M A. Etiology and antimicrobial treatment of acute sinusitis. Ann Otol Rhinol Laryngol. 90:1981;68-71.
3. Lund V J. Bacterial sinusitis: etiology and surgical management. Ped Infect Dis J. 13:1994;S58-63.
4. Kankam C G, Sallis R. Acute sinusitis in adults. Difficult to diagnose, essential to treat. Postgrad Med. 102:1997;252-258.
5. Gwaltney J M. Acute community-acquired sinusitis. Clin Infect Dis. 23:1996;1209-1225.
6. Lindboek M, Hjortdahl P, Johnsen U L. Use of symptoms, signs, and blood tests to diagnose acute sinus infections in primary care: comparison with computed tomography. Fam Med. 28:1996;183-188.
7. Diaz I, Bamberger D M. Acute sinusitis. Sem Respir Infect. 10:1995;14-20.
8. Jousimies-Somer H R, Savolainen S, Ylikoski J S. Comparison of the nasal flora in two groups of healthy subjects and in patients with acute maxillary sinusitis. J Clin Microbiol. 27:1989;2736-2743.
9. Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother. 38:1996;117-132.
10. Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother. 39:1997;1-6.
11. Doern G V. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med. 99:1995;3S-7S.
12. Cockburn J, Reid A L, Bowman J A, Sanson-Fisher R W. Effects of intervention on antibiotic compliance in patients in general practice. Med J Aust. 147:1987;324-328.
13. Greenberg R N. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 6:1994;592-599.
14. Martel A M, Leeson P A, Castaner J. BAY-12-8039, fluoroquinolone antibacterial. Drugs of the Future. 22:1997;109-113.
15. Woodcock J M, Andrews J M, Boswell F J, Brenwald N P, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother. 41:1997;101-106.
16. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy. 42:1996;410-425.
17. Staß H, Dalhoff A, Kubitza D, Schuhly U. Pharmakokinetics, safety, and tolerability of ascending single dose of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 42:1998;2060-2065.
18. Brueggemann A B, Kugler K C, Doern G V. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones againstStreptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother. 41:1997;1594-1597.
19. Pakes G E, Graham J A, Rauch A M, Collins J J. Cefuroxime axetil in the treatment of sinusitis. A review. Arch Fam Med. 3:1994;165-175.
20. van Buchem F L, Knottnerus J A, Schrijemaekers V JJ, Peeters M F. Primary-care-based randomised placebo-controlled trail of antibiotic treatment in acute maxillary sinusitis. Lancet. 349:1997;683-687.
21. Poole M D. Antimicrobial therapy for sinusitis. Otolaryngol Clin North Am. 30:1997;331-339.
22. Williams J W, Roberts L, Distell B, Simel D L. Diagnosing sinusitis by X-ray: is a single Waters' view adequate? J Gen Intern Med. 7:1992;481-485.
23. Burke T F, Guertler A T, Timmons J H. Comparison of sinus X-rays with computed tomography scans in acute sinusitis. Acad Emerg Med. 1:1994;235-239.
24. Hartog B, Van Bentham P P, van Waes P F, Ten Hove W, Hordijk G J. Value of sinus radiographs in the diagnosis of maxillary sinus disease: interobserver agreement on sinus radiographs by otolaryngologists and radiologists. Clin Otolaryngol. 6:1996;495-498.
25. Andrews, J, Honeybourne, D, Jevons, G, Wise, R, Penetration of moxifloxacin into bronchial mucosa, epithelial lining fluid and alveolar macrophages following a single, 400-mg dose, 38th Intersci Confer Antimicrob Agents Chemother, 1998.
26. Guillemot D, Carbon C, Balkau B. Low dosage and long treatment duration of β -lactam: risk factors for carriage of penicillin-resistantStreptococcus pneumococci. JAMA. 279:1998;365-370.
27. Pichichero M e, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Ped Infect Dis J. 16:1997;680-695.